623 related articles for article (PubMed ID: 29284347)
21. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
Wu EQ; Guerin A; Yu AP; Bollu VK; Guo A; Griffin JD
Curr Med Res Opin; 2010 Dec; 26(12):2861-9. PubMed ID: 21062136
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
24. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Guérin A; Chen L; Wu EQ; Ponce de Leon D; Griffin JD
Curr Med Res Opin; 2012 Jul; 28(7):1155-62. PubMed ID: 22738777
[TBL] [Abstract][Full Text] [Related]
25. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
26. A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia.
Cantoni N; Sommavilla R; Seitz P; Kulenkampff E; Kahn S; Lambert JF; Schmidt A; Zenhaeusern R; Balabanov S
BMC Cancer; 2022 Nov; 22(1):1192. PubMed ID: 36402993
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
[TBL] [Abstract][Full Text] [Related]
28. Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.
Knopf KB; Divino V; McGarry L; Chen YJ; Pokras S; Munakata J; Taylor C; Ng D; Nieset C; Huang H
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e163-71. PubMed ID: 26411541
[TBL] [Abstract][Full Text] [Related]
29. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
Ribeiro BF; Miranda EC; Albuquerque DM; Delamain MT; Oliveira-Duarte G; Almeida MH; Vergílio B; Silveira RA; Oliveira-Duarte V; Lorand-Metze I; De Souza CA; Pagnano KB
Clinics (Sao Paulo); 2015 Aug; 70(8):550-5. PubMed ID: 26247667
[TBL] [Abstract][Full Text] [Related]
30. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
Ward MA; Fang G; Richards KL; Walko CM; Earnshaw SR; Happe LE; Blalock SJ
Curr Med Res Opin; 2015 Feb; 31(2):289-97. PubMed ID: 25420131
[TBL] [Abstract][Full Text] [Related]
31. Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia.
Machado-Alba JE; Machado-Duque ME
Int J Clin Pharm; 2017 Aug; 39(4):851-859. PubMed ID: 28508322
[TBL] [Abstract][Full Text] [Related]
32. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
33. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary hypertension in patients with chronic myeloid leukemia.
Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Sun BJ; Park JH; Jeong JO; Jo DY
Medicine (Baltimore); 2021 Aug; 100(33):e26975. PubMed ID: 34414970
[TBL] [Abstract][Full Text] [Related]
36. [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].
Yuan T; Lai YY; Qin YZ; Shi HX; Huang XJ; Hou Y; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):93-99. PubMed ID: 32135623
[No Abstract] [Full Text] [Related]
37. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
Eghtedar A; Kantarjian H; Jabbour E; O'Brien S; Burton E; Garcia-Manero G; Verstovsek S; Ravandi F; Borthakur G; Konopleva M; Quintas-Cardama A; Cortes J
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):477-84. PubMed ID: 23770156
[TBL] [Abstract][Full Text] [Related]
38. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Clark RE; Polydoros F; Apperley JF; Milojkovic D; Rothwell K; Pocock C; Byrne J; de Lavallade H; Osborne W; Robinson L; O'Brien SG; Read L; Foroni L; Copland M
Lancet Haematol; 2019 Jul; 6(7):e375-e383. PubMed ID: 31201085
[TBL] [Abstract][Full Text] [Related]
39. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
[TBL] [Abstract][Full Text] [Related]
40. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
Ongoren S; Eskazan AE; Suzan V; Savci S; Erdogan Ozunal I; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Erbilgin Y; Iseri SA; Ar MC; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Hematology; 2018 May; 23(4):212-220. PubMed ID: 28990873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]